The London Clinic is developing access to emerging, innovative, therapies for pancreatic cancer – one of the most challenging cancers to treat.
Opening new doors for pancreatic cancer patients
18 November 2026
Start typing what you're looking for using phrases or keywords
Filters:
18 November 2026
The London Clinic is developing access to emerging, innovative, therapies for pancreatic cancer – one of the most challenging cancers to treat.
Patients with pancreatic cancer will be able to benefit from innovative, emerging therapies, not yet commercially available, through an access programme being developed by The London Clinic.
Pancreatic cancer remains one of the most challenging cancers to treat, as it is frequently diagnosed at an advanced stage. Cancer Research stats show there are 10,200 deaths in the UK and almost 11,500 new cases diagnosed each year.
The drug – daraxonrasib – manufactured by RASONQUET ™ – is a treatment option for patients with metastic cancer which has spread to other parts of the body.
Daraxonrasib is being made available through an international named-patient access programme (NPAPs); which is a regulatory pathway, allowing a doctor access to a medicine not yet approved or commercially available. Available in the US, in the UK daraxonrasib is being used in clinical trials but isn’t routinely available on the NHS.
Leading the access initiative is Dr Khurum Khan, Consultant Medical Oncologist and Director of Cancer Genomics at The London Clinic. Dr Khan is also Clinical Associate Professor at Northwestern University Feinberg School of Medicine.
Dr Khan said, “One of the most important developments is our growing understanding of the genetic changes that drive this disease. KRAS, a gene responsible for driving cancer growth, was once considered ‘undruggable’, meaning that scientists believed it was almost impossible to develop medicines that could effectively target it.
Today, advances in drug development are beginning to challenge that belief, with new treatments showing that it is possible to exploit the cancer’s dependence on these genetic changes.”
Cancer treatment should not necessarily be viewed as a single, finite course of chemotherapy.Dr Khurum Khan
Dr Khan has been working in partnership with Consultant Medical Oncologist, Dr Timothy Crook, offering patients the opportunity to have extended genomic profiling coupled with targeted therapies.
By understanding the unique genetic makeup of an individual’s cancer through advanced genomic testing, it becomes increasingly easier to identify the biological weaknesses of a tumour and select treatments designed to target them.
For patients with locally advanced or metastatic disease, systemic chemotherapy remains the mainstay of treatment. Depending on the patient’s fitness and clinical circumstances, commonly used first-line regimens include FOLFIRINOX or gemcitabine-based combinations.
Dr Khan said he feels strongly about the importance of looking beyond first-line chemotherapy, and said, “Cancer treatment should not necessarily be viewed as a single, finite course of chemotherapy.”
As the disease evolves, different chemotherapy combinations may be appropriate, depending on previous treatment exposure, response, cumulative toxicity, performance status and, importantly, the patient’s wishes.
In selected patients, this can involve several different lines of treatment and alternative chemotherapy combinations.
Dr Khurum Khan explored the potential value of extended and sequential chemotherapy in medical journal, Cancers in 2025.
Dr Khan said, “Our ambition at The London Clinic is to bring these advances in genomic science, innovative treatments and academic research closer to patients, ensuring that they benefit from the latest discoveries and the opportunities offered by precision oncology, genomic profiling and exploring emerging treatment opportunities for patients with difficult-to-treat cancers.”
Find out more about our cancer care services here, and book an appointment with Dr Khurum Khan via his profile below.